Exploring the Epidemiology and Awareness of Metabolic dysfunction-associated steatotic liver disease (MASLD) Among Health Sciences Students in an academic health care institute in India.

Metabolism Open, Journal Year: 2024, Volume and Issue: 24, P. 100325 - 100325

Published: Oct. 18, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 25 % of the global population, presenting a significant health challenge. It is often asymptomatic but linked to severe conditions like cirrhosis and cancer. Previous research indicates that people underestimate MASLD risks. This study examines prevalence awareness among medical students in an academic care institute India.

Language: Английский

Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction

Expert Opinion on Investigational Drugs, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 12, 2024

Glucagon-like peptide-1 receptor (GLP-1 R) agonists have demonstrated remarkable effectiveness in the treatment of obesity and type 2 diabetes. Although these agents provide beneficial effects for metabolic dysfunction-associated steatohepatitis (MASH) through their glucose-lowering weight-reducing properties, efficacy promoting fibrosis regression remains unproven. Survodutide, an investigational dual agonist that simultaneously targets both glucagon (GCGR) GLP-1 R, has emerged as a promising therapeutic candidate comprehensive management MASH. By engaging two critical receptors, this drug potential to offer broad spectrum benefits, addressing multiple pathogenic mechanisms underlying interrelated disorders.

Language: Английский